Sarine FY2025 revenue falls 25% to USD 29.6 million

Reuters
02/27
Sarine FY2025 revenue falls 25% to USD 29.6 million

Sarine reported FY2025 revenue of USD 29.6 million (25% decline) and a net loss of USD 3.9 million, which it said was affected by a USD 1.4 million non-cash tax expense and an inventory write-down of just over USD 2.0 million. EBITDA was USD 1.2 million and cashflow from operating activities was positive at USD 4.5 million. The company said FY2025 was pressured by disruption from lab-grown diamonds in the U.S. and weak consumer sentiment in China, with lower natural diamond polishing volumes weighing on capital equipment sales and Galaxy-related scanning revenues. Sarine said it expects FY2026 cost savings of an estimated USD 1.5 million from moving manufacturing and support operations to India, and is cautiously optimistic as late-2025 and early-2026 data indicate an initial rebound in natural diamond demand. It also highlighted wider adoption of its MVP cloud-based rough diamond optimisation offering and growth opportunities for its GCAL grading business, including demand for higher-end lab-grown diamond reports and expanded jewellery evaluation services. Sarine-added Kitov.ai is scheduled to launch its Prime product in Q2 2026 and is targeting operational break-even toward the end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarine Technologies Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 13SYKGH56NF7DSP5) on February 27, 2026, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10